目的系统评价糖脉康辅助治疗2型糖尿病(T2DM)对血糖相关指标的改善效果,为中医药治疗T2DM提供循证医学参考。方法以糖脉康、中药复方制剂、西医降糖药物、2型糖尿病为中文检索词,以Tang Mai Kang、Tangmaikang、antidiabetic drugs、hyp...目的系统评价糖脉康辅助治疗2型糖尿病(T2DM)对血糖相关指标的改善效果,为中医药治疗T2DM提供循证医学参考。方法以糖脉康、中药复方制剂、西医降糖药物、2型糖尿病为中文检索词,以Tang Mai Kang、Tangmaikang、antidiabetic drugs、hypoglycemic agents、granule of traditional Chinese medicine、traditional Chinese medicine granules、diabetes mellitus、T2DM、diabetes mellitus type 2、diabetes patient、diabetes mellitus patient、type 2 diabetes mellitus、T2DM为英文检索词,计算机检索中国生物医学文献数据库、中国期刊全文数据库、万方数字化期刊全文数据库及中文科技期刊数据库数据库、Medline、EMBASE、The Cochrane Library等,收集糖脉康辅助治疗与西医治疗T2DM疗效对比的随机对照文献,提取纳入研究的特征信息。用Revman5.2软件进行Meta分析,比较糖脉康辅助治疗与西医治疗对空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(Hb A_(1c))的效果。结果共纳入10篇文献。采用糖脉康辅助治疗2个月时T2DM患者的FBG(95%CI为-0.62^-0.33)及治疗3个月时的2 h PG(95%CI为-0.84^-0.47)、Hb A_(1c)(95%CI为-0.45^-0.22)均低于采用西医降糖药物者(P均<0.01)。结论采用糖脉康辅助治疗的T2DM患者FBG、2 h PG、Hb A_(1c)均低于采用西医降糖药物者。展开更多
目的:系统评价糖脉康颗粒/片联合常规降糖药治疗糖尿病肾脏病(DKD)的疗效,为临床提供循证参考。方法:计算机检索Medline、EMBase、Cochrane图书馆、中国生物医学文献数据库、中国期刊全文数据库、万方数据库和中文科技期刊数据库,收集...目的:系统评价糖脉康颗粒/片联合常规降糖药治疗糖尿病肾脏病(DKD)的疗效,为临床提供循证参考。方法:计算机检索Medline、EMBase、Cochrane图书馆、中国生物医学文献数据库、中国期刊全文数据库、万方数据库和中文科技期刊数据库,收集糖脉康颗粒/片联合常规降糖药(试验组)对比单用常规降糖药(对照组)治疗DKD的相关试验,提取资料并进行质量评价后,采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入9项RCT,合计883例患者。Meta分析结果显示,试验组患者临床有效率显著高于对照组[OR=4.88,95%CI(2.56,9.32),P<0.001],血肌酐(Scr)[MD=-28.48,95%CI(-34.90,-22.06),P<0.001]和24 h尿蛋白定量[MD=-100.26,95%CI(-106.00,-94.52),P<0.001]显著低于对照组,差异均有统计学意义。两组患者血尿素氮(BUN)水平比较差异无统计学意义[MD=-0.85,95%CI(-1.36,-0.34),P=0.001]。结论:糖脉康颗粒/片联合常规降糖药治疗DKD的疗效较好,可降低患者的Scr和24 h尿蛋白定量。展开更多
OBJECTIVE: To systematically assess the effect of new exercise of Health Qigong(NEHQ) on fasting plasma glucose(FPG), 2 hour postprandial plasma glucose(2 hPG), Hemoglobin A1C(HbA1C), triglycerides(TG), total choleste...OBJECTIVE: To systematically assess the effect of new exercise of Health Qigong(NEHQ) on fasting plasma glucose(FPG), 2 hour postprandial plasma glucose(2 hPG), Hemoglobin A1C(HbA1C), triglycerides(TG), total cholesterol(TC), low density lipoprotein(LDL), and high density lipoprotein(HDL)in patients with type 2 diabetes mellitus(T2DM).METHODS: Data were retrieved by searching EMBASE,MEDLINE, The Cochrane Library, China Biology Medicine,China National Knowledge Infrastructure, Wanfang Data and Chongqing VIP Database. The random-ized controlled trials(RCTs) related to NEHQ were searched. The search terms were "fasting plasma glucose","2 hour postprandial plasma glucose","Hemoglobin A1C","TG(triglycerides)","total cholesterol","low density lipoprotein",and "high density lipoprotein". Meta-analysis were conducted with the Collaboration's Revman 5.3.RESULTS: Fourteen RCTs including 999 patients were analyzed. The levels of FPG in the patients with the intervention of NEHQ-Ba Duan Jin in 2, 6, 9 months respectively, and of NEHQ·Mawangdui Daoyin in 12 months were lower than those in the control group(P<0.05); the levels of 2hPG in the patients with the intervention of NEHQ-Ba Duan Jin in 2, 4, 6 months respectively were lower than those in the control group(P<0.05);the levels of HbAlc in the patients with the intervention of NEHQ·Ba Duan Jin in 2, 3, 4, 6, 9 months respectively, and of NEHQ·Mawangdui Daoyin 12 months were lower than those in the control group(P<0.05); the levels of TG in the patients with the intervention of NEHQ·Ba Duan Jin in 4 and 6 months respectively, and of NEHQ·Mawangdui Daoyin in 12 months were lower than those in the control group(P<0.05);the levels of TC in the patients with the intervention of NEHQ·Ba Duan Jin in 2,6, 9 months respectively were lower than those in the control group(P<0.05); the levels of LDL in the patients with the intervention of NEHQ-Ba Duan Jin in 3 and 6 months respectively were lower than those in the control group(P<0.05);the level of HDL in the patients with the intervention of NEHQ·Mawangdui Daoyin in 12 months was higher than those in the control group(P<0.05).CONCLUSION: The outcomes of the patients with T2DM in NEHQ group was better than those in the control group in terms of FPG, 2hPG, HbA1C, TQ LDL, and HDL.展开更多
文摘目的系统评价糖脉康辅助治疗2型糖尿病(T2DM)对血糖相关指标的改善效果,为中医药治疗T2DM提供循证医学参考。方法以糖脉康、中药复方制剂、西医降糖药物、2型糖尿病为中文检索词,以Tang Mai Kang、Tangmaikang、antidiabetic drugs、hypoglycemic agents、granule of traditional Chinese medicine、traditional Chinese medicine granules、diabetes mellitus、T2DM、diabetes mellitus type 2、diabetes patient、diabetes mellitus patient、type 2 diabetes mellitus、T2DM为英文检索词,计算机检索中国生物医学文献数据库、中国期刊全文数据库、万方数字化期刊全文数据库及中文科技期刊数据库数据库、Medline、EMBASE、The Cochrane Library等,收集糖脉康辅助治疗与西医治疗T2DM疗效对比的随机对照文献,提取纳入研究的特征信息。用Revman5.2软件进行Meta分析,比较糖脉康辅助治疗与西医治疗对空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(Hb A_(1c))的效果。结果共纳入10篇文献。采用糖脉康辅助治疗2个月时T2DM患者的FBG(95%CI为-0.62^-0.33)及治疗3个月时的2 h PG(95%CI为-0.84^-0.47)、Hb A_(1c)(95%CI为-0.45^-0.22)均低于采用西医降糖药物者(P均<0.01)。结论采用糖脉康辅助治疗的T2DM患者FBG、2 h PG、Hb A_(1c)均低于采用西医降糖药物者。
文摘目的:系统评价糖脉康颗粒/片联合常规降糖药治疗糖尿病肾脏病(DKD)的疗效,为临床提供循证参考。方法:计算机检索Medline、EMBase、Cochrane图书馆、中国生物医学文献数据库、中国期刊全文数据库、万方数据库和中文科技期刊数据库,收集糖脉康颗粒/片联合常规降糖药(试验组)对比单用常规降糖药(对照组)治疗DKD的相关试验,提取资料并进行质量评价后,采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入9项RCT,合计883例患者。Meta分析结果显示,试验组患者临床有效率显著高于对照组[OR=4.88,95%CI(2.56,9.32),P<0.001],血肌酐(Scr)[MD=-28.48,95%CI(-34.90,-22.06),P<0.001]和24 h尿蛋白定量[MD=-100.26,95%CI(-106.00,-94.52),P<0.001]显著低于对照组,差异均有统计学意义。两组患者血尿素氮(BUN)水平比较差异无统计学意义[MD=-0.85,95%CI(-1.36,-0.34),P=0.001]。结论:糖脉康颗粒/片联合常规降糖药治疗DKD的疗效较好,可降低患者的Scr和24 h尿蛋白定量。
基金Research Project for Practice Development of National Traditional Chinese Medicine Clinical Research Bases(Grant No.:JDZX2012128)
文摘OBJECTIVE: To systematically assess the effect of new exercise of Health Qigong(NEHQ) on fasting plasma glucose(FPG), 2 hour postprandial plasma glucose(2 hPG), Hemoglobin A1C(HbA1C), triglycerides(TG), total cholesterol(TC), low density lipoprotein(LDL), and high density lipoprotein(HDL)in patients with type 2 diabetes mellitus(T2DM).METHODS: Data were retrieved by searching EMBASE,MEDLINE, The Cochrane Library, China Biology Medicine,China National Knowledge Infrastructure, Wanfang Data and Chongqing VIP Database. The random-ized controlled trials(RCTs) related to NEHQ were searched. The search terms were "fasting plasma glucose","2 hour postprandial plasma glucose","Hemoglobin A1C","TG(triglycerides)","total cholesterol","low density lipoprotein",and "high density lipoprotein". Meta-analysis were conducted with the Collaboration's Revman 5.3.RESULTS: Fourteen RCTs including 999 patients were analyzed. The levels of FPG in the patients with the intervention of NEHQ-Ba Duan Jin in 2, 6, 9 months respectively, and of NEHQ·Mawangdui Daoyin in 12 months were lower than those in the control group(P<0.05); the levels of 2hPG in the patients with the intervention of NEHQ-Ba Duan Jin in 2, 4, 6 months respectively were lower than those in the control group(P<0.05);the levels of HbAlc in the patients with the intervention of NEHQ·Ba Duan Jin in 2, 3, 4, 6, 9 months respectively, and of NEHQ·Mawangdui Daoyin 12 months were lower than those in the control group(P<0.05); the levels of TG in the patients with the intervention of NEHQ·Ba Duan Jin in 4 and 6 months respectively, and of NEHQ·Mawangdui Daoyin in 12 months were lower than those in the control group(P<0.05);the levels of TC in the patients with the intervention of NEHQ·Ba Duan Jin in 2,6, 9 months respectively were lower than those in the control group(P<0.05); the levels of LDL in the patients with the intervention of NEHQ-Ba Duan Jin in 3 and 6 months respectively were lower than those in the control group(P<0.05);the level of HDL in the patients with the intervention of NEHQ·Mawangdui Daoyin in 12 months was higher than those in the control group(P<0.05).CONCLUSION: The outcomes of the patients with T2DM in NEHQ group was better than those in the control group in terms of FPG, 2hPG, HbA1C, TQ LDL, and HDL.
